Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eloxx Pharmaceuticals Inc (ELOX)

Eloxx Pharmaceuticals Inc (ELOX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 2
  • Shares Outstanding, K 3,143
  • Annual Sales, $ 0 K
  • Annual Income, $ -36,070 K
  • 60-Month Beta 2.61
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ELOX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -9.07
  • Most Recent Earnings $-1.31 on 11/13/23
  • Next Earnings Date 09/23/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0006 unch
on 09/09/24
0.0040 -85.00%
on 09/09/24
N/A (-99.91%)
since 08/09/24
3-Month
0.0006 unch
on 09/09/24
0.8400 -99.93%
on 07/09/24
-0.6850 (-99.91%)
since 06/07/24
52-Week
0.0006 unch
on 09/09/24
5.9900 -99.99%
on 09/18/23
-5.3494 (-99.99%)
since 09/08/23

Most Recent Stories

More News
This Small Cap Stock Surged Over 100%

Shares of Eloxx Pharmaceuticals (NASDAQ: ELOX) rocketed almost 100% on Tuesday after receiving an increased price target from Oppenheimer.

ELOX : 0.0006 (-99.91%)
Eloxx Pharmaceuticals Announces Changes to Board of Directors

Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures Gadi...

ELOX : 0.0006 (-99.91%)
Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update

Cystic Fibrosis Foundation (CF Foundation) awarded up to $15.9 million for the ongoing ELX-02 clinical program Topline data from cystic fibrosis (CF)...

ELOX : 0.0006 (-99.91%)
Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update

Expect topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor by the end of the first half of 2022 ...

ELOX : 0.0006 (-99.91%)
Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome

Strong rationale for development for Alport syndrome as ELOX-02 has demonstrated significant readthrough in COL4A5 nonsense mutations in preclinical...

ELOX : 0.0006 (-99.91%)
Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation

Cystic Fibrosis Foundation (CF Foundation) to provide an award of up to $15.9 million for the ongoing ELX-02 clinical program Expect topline data from...

ELOX : 0.0006 (-99.91%)
Eloxx Pharmaceuticals Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update

Data from Monotherapy Arms of Ongoing Phase 2 ELX-02 Cystic Fibrosis (CF) Clinical Trials Expected in Fourth Quarter of 2021 Received...

ELOX : 0.0006 (-99.91%)
Eloxx Pharmaceuticals to Host Investor and Analyst Call and Webcast on Cystic Fibrosis Programs

Globally renowned CF Expert, Dr. Eitan Kerem will provide key insights Data from ongoing Phase 2 trials in CF expected in 4Q 2021 WATERTOWN, Mass., Oct. ...

ELOX : 0.0006 (-99.91%)
Why Pharmaceutical Companies in Ovarian Cancer Drugs Market are Betting Big on R&D

Palm Beach, FL – September 17, 2021 – FinancialNewsMedia.com News Commentary – The ovarian cancer drugs market consists of sales of ovarian cancer drugs to treat ovarian cancer. Ovarian cancer...

BIOV.CN : 0.0700 (+7.69%)
BVAXF : 0.0515 (+16.52%)
LPTX : 2.84 (-1.39%)
PHIO : 3.55 (-3.01%)
LIFE : 1.9000 (+2.70%)
ELOX : 0.0006 (-99.91%)
Eloxx Pharmaceuticals Announces Fast Track Designation for ELX-02 for the Treatment of Cystic Fibrosis Patients with Nonsense Mutations

WATERTOWN, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for...

ELOX : 0.0006 (-99.91%)

Business Summary

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed...

See More

Key Turning Points

3rd Resistance Point 0.0063
2nd Resistance Point 0.0051
1st Resistance Point 0.0029
Last Price 0.0006
1st Support Level N/A
2nd Support Level N/A
3rd Support Level N/A

See More

52-Week High 5.9900
Fibonacci 61.8% 3.7020
Fibonacci 50% 2.9953
Fibonacci 38.2% 2.2886
Last Price 0.0006
52-Week Low 0.0006

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar